IL-4 receptor antagonist monoclonal antibody

This page covers all IL-4 receptor antagonist monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-4 receptor alpha (IL-4Rα), IL-4Rα (Interleukin-4 receptor alpha).

Targets

IL-4 receptor alpha (IL-4Rα) · IL-4Rα (Interleukin-4 receptor alpha)

Marketed (4)

• Dupilumab Injectable Product · University of Virginia · Immunology
  Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of interleukin-4 and interleukin-13 to reduce type 2 inflammatory responses.
• Dupilumab (SAR231893) · Sanofi · Immunology
  Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of interleukin-4 and interleukin-13, key drivers of type 2 inflammation.
• Dupilumab - Dose Reduction · Johns Hopkins University · Immunology
  Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.
• Dupilumab step-down · Nantes University Hospital · Immunology / Allergy / Dermatology
  Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.

Phase 3 pipeline (2)

• Placebo matching depemokimab · GlaxoSmithKline · Immunology / Allergy / Respiratory
  Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.
• Depemokimab (GSK3511294) · GlaxoSmithKline · Immunology / Allergy / Respiratory
  Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.